InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.170 0.005 (2.86%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$102 Shares released from escrow 21 Apr 2016 10:33AM $0.320 $0.170 fallen by 46.88%
$102 Appendix 4C - quarterly 14 Apr 2016 2:54PM $0.300 $0.170 fallen by 43.33%
$102 Paradigms Updated Investor Presentation 16 Mar 2016 9:10AM $0.305 $0.170 fallen by 44.26%
$102 Change of Director's Interest Notice 15 Mar 2016 7:25PM $0.305 $0.170 fallen by 44.26%
$102 Change in substantial holding 15 Mar 2016 7:21PM $0.305 $0.170 fallen by 44.26%
$102 Paradigm initiates second clinical trial site 2 Mar 2016 8:36AM $0.275 $0.170 fallen by 38.18%
$102 Half Yearly Report and Accounts 25 Feb 2016 2:15PM $0.280 $0.170 fallen by 39.29%
$102 First Participant treated in Paradigms Clinical Trial 25 Feb 2016 8:41AM $0.280 $0.170 fallen by 39.29%
$102 Paradigm starts Clinical Trial 23 Feb 2016 9:08AM $0.280 $0.170 fallen by 39.29%
$102 Appendix 4C - quarterly 27 Jan 2016 11:42AM $0.320 $0.170 fallen by 46.88%
$102 European Patent Office Grants PAR Key Respiratory Patent 15 Dec 2015 9:19AM $0.310 $0.170 fallen by 45.16%
$102 Appendix 3Y 14 Dec 2015 5:16PM $0.310 $0.170 fallen by 45.16%
$102 Elite Athlete successfully treated with Paradigm's Zilosul 3 Dec 2015 9:52AM $0.320 $0.170 fallen by 46.88%
$102 Paradigm Biopharmaceuticals Receives Ethics Approval 23 Nov 2015 10:45AM $0.330 $0.170 fallen by 48.48%
$102 Appendix 3B - Release from escrow 10 Nov 2015 1:41PM $0.320 $0.170 fallen by 46.88%
$102 Results of Meeting 30 Oct 2015 3:38PM $0.280 $0.170 fallen by 39.29%
$102 CEO AGM Presentation 30 Oct 2015 11:03AM $0.280 $0.170 fallen by 39.29%
$102 Appendix 4C - quarterly 28 Oct 2015 11:48AM $0.280 $0.170 fallen by 39.29%
$102 Shares released from escrow 22 Oct 2015 2:02PM $0.300 $0.170 fallen by 43.33%
$102 Notice of Annual General Meeting/Proxy Form 28 Sep 2015 11:29AM $0.300 $0.170 fallen by 43.33%
$102 Appendix 4G 28 Sep 2015 11:19AM $0.300 $0.170 fallen by 43.33%
$102 2015 Annual Report 28 Sep 2015 11:13AM $0.300 $0.170 fallen by 43.33%
$102 Preliminary Final Report 31 Aug 2015 3:39PM $0.330 $0.170 fallen by 48.48%
$102 Paradigm Secures Key US Patent 26 Aug 2015 9:59AM $0.310 $0.170 fallen by 45.16%
$102 Becoming a substantial holder 24 Aug 2015 11:31AM $0.350 $0.170 fallen by 51.43%

676 - 700 of 720 results

Page 28 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.